Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
Our top-notch dedicated system is used to design specialised libraries for receptors.
Fig. 1. The sreening workflow of Receptor.AI
It includes extensive molecular simulations of the receptor in its native membrane environment and the ensemble virtual screening accounting for its conformational mobility. In the case of dimeric or oligomeric receptors, the whole functional complex is modelled, and the tentative binding pockets are determined on and between the subunits to cover the whole spectrum of possible mechanisms of action.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q13324
UPID:
CRFR2_HUMAN
Alternative names:
Corticotropin-releasing hormone receptor 2
Alternative UPACC:
Q13324; B2R967; B3SXS6; B3SXS7; B3SXS8; B3SXT0; F8WA81; O43461; Q4QRJ4; Q99431
Background:
Corticotropin-releasing factor receptor 2 (CRFR2) is a pivotal G-protein coupled receptor, recognizing CRH, UCN, UCN2, and UCN3 with high affinity for UCN. This interaction induces a conformational change, initiating signaling through G proteins and downstream effectors like adenylate cyclase, thereby elevating intracellular cAMP levels.
Therapeutic significance:
Understanding the role of Corticotropin-releasing factor receptor 2 could open doors to potential therapeutic strategies.